ePoster P-115 “Sequential treatment with sorafenib followed by regorafenib in patients with unresectable hepatocellular carcinoma (HCC): Interim analysis of the observational REFINE study”

This poster shows data from an interim analysis of the REFINE study, an ongoing, prospective, observational, post-authorization safety study designed to evaluate the safety and effectiveness of sequential treatment with sorafenib followed by regorafenib in patients with unresectable HCC in real-world practice.